Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U
    Session Type: B2B

    7th B2B Uro-Oncology: GU Cancers Triad Meeting - Five Practice-Changing Advances on the Horizon

    Friday, October 31, 2025
    16:25 - 17:30 GMT+0

    Bench-to-Bedside SIU@U

    This educational programme is supported by:
    B2B Presenting Sponsors: Daiichi-Sankyo | AstraZeneca, Johnson & Johnson
    B2B Contributing Sponsors: Bristol Myers Squibb, CG Oncology, Ferring Pharmaceuticals, Merck Sharp & Dohme LLC, Novartis AG

    B2B Scientific Programme Committee: Peter Black, Canada / Caroline Moore, United Kingdom / Simon Tanguay, Canada

    Learning Objectives :

    At the end of this session, attendees should be able to:
    • Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
    • Recognize the role of imaging and genetic markers in guiding treatment decision-making.
    • Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
    • Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
    • Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

    Presentations:

    • 16:25 - 16:45 GMT+0
      Bladder Cancer

      Speaker: Kilian Martin Gust – Austria

    • 16:45 - 17:05 GMT+0
      Kidney Cancer

      Speaker: Axel Bex – University College London

    • 17:05 - 17:25 GMT+0
      Prostate Cancer

      Speaker: Robert Jones – University of Glasgow

    • 17:25 - 17:30 GMT+0
      Closing Remarks

      Moderator: Peter Black – University of British Columbia

      Moderator: Simon Tanguay – McGill University